Severe acute cardiogenic pulmonary edema (ACPE) can successfully be treated with noninvasive pressure support ventilation (NIPSV) in a clinical setting. Whether prehospital NIPSV starting early at patients' home and being continued until hospital arrival is feasible and improves ACPE emergency care is examined in this study. End points of the study were oxygen saturation at hospital admission and clinical outcome. Twenty-three patients suffering from severe cardiac pulmonary edema with severe dyspnea, an oxygen saturation of less than 90% and basal rales were included in this controlled prospective randomized trial. All patients received standard medical treatment and 10 patients were additionally treated with NIPSV (pressure support level, 12 cmH 2 O; positive endexpiratory pressure, 5 cmH 2 O; FiO 2 , 0.6) whereas the other patients received oxygen (8 l/min) via Venturi face mask. Improvement in oxygen saturation was significantly faster in the NIPSV group and oxygen saturation was higher at the time of the hospital admission (NIPSV = 97.3 ± 0.8%; standard = 89.5 ± 2.7%, P = 0.002). A trend toward higher troponin T levels was seen in the standard treatment group. The need for intensive care treatment did not differ, and one patient of each treatment group died in hospital. No complications were noted during the treatment with NIPSV. Prehospital NIPSV is feasible and able to improve emergency management of ACPE.
Introduction
Noninvasive pressure support ventilation (NIPSV) is a well acknowledged advancement in the treatment of acute cardiogenic pulmonary edema (ACPE) in a clinical setting. It rapidly and substantially improves oxygen saturation, arterial pH and partial pressure of carbon dioxide (PaCO 2 ) without serious side effects [1] . It has been reported that noninvasive ventilation corrects PaCO 2 , arterial pH and dyspnea scores more efficiently than continuous positive airway pressure (CPAP) and results in a rapid normalization of heart rate and blood pressure [2] . Initial concerns regarding a higher rate of myocardial infarction in noninvasively ventilated patients [2] as compared with patients treated with CPAP have not been substantiated in recent larger studies [3, 4] .
One study, however, demonstrated a higher in-hospital mortality in patients treated with noninvasive bilevel ventilation as compared with patients treated with CPAP [5] .
A fully developed pulmonary edema with typical radiographic signs, respiratory distress and hypoxia at the time of hospital admission is known to have an unfavorable prognosis [6] and prompt initiation of treatment is essential to stop devastating deterioration. As effects of noninvasive ventilation in cardiac pulmonary edema occur rapidly within minutes after its initiation [1] , patients could profit more the earlier the ventilatory support is started. Thus, an optimized prehospital treatment is likely to improve outcome of patients with acute heart failure. On the other hand, it is possible that such a treatment prolongs patient treatment outside hospital and is not well tolerated in a prehospital setting. Several retrospective studies have shown a beneficial effect of CPAP in a prehospital emergency setting [7, 8] . Poor results have been reported for prehospital bilevel positive airway ventilation (BiPAP) compared with treatment with high-dose intravenous isosorbide dinitrate in severe pulmonary edema [9] . This study was discontinued because of a higher mortality rate, need for intubation and myocardial infarction and a lower increase of oxygen saturation in the BiPAP-treated group. Prehospital NIPSV, however, has never been evaluated prospectively. This study was designed to evaluate the effectiveness and feasibility of prehospital NIPSV added on a standard therapy in acute pulmonary edema.
Methods
Twenty-three patients who called the emergency service because of severe dyspnea and consecutively showed additional clinical signs of ACPE (SpO 2 less than 90% and basal rales) were included in the study after informed consent. The emergency team consisted of two paramedics and one physician trained in emergency medicine and familiar with NIPSV. After diagnosis of ACPE, patients were randomly assigned to either additional ventilatory support or standard therapy only. Exclusion criteria were severe uncontrolled agitation, angina, obvious ST elevation in the ECG, emesis and aspiration, cardiogenic shock, life threatening arrhythmias, coma or any obvious need for intubation. Patients were placed in a semirecumbent position and received an intravenous access. All patients were treated with standard drugs for acute heart failure and the standard therapy group received oxygen (8 l/min) via Venturi face mask. In the NIPSV group, a transportable ventilator (Oxylog 3000, Dräger Medical Lübeck, Germany) was connected to a hermetic face mask (Dräger Medical Lübeck, Germany) and noninvasive ventilation was started as early as possible at the patients' home. The ventilator compensates minor mask leakages. An initial pressure support of 12 cmH 2 O and a positive end expiratory pressure of 5 cmH 2 O was applied. The oxygen fraction (FiO 2 ) was 0.6 (comparable to the FiO 2 delivered by a Venturi face mask with an oxygen supply of 8 l/min) and the flow trigger was 3 l/min. The pressure support was adjusted according to the tidal volume to obtain a volume of at least 7-ml/kg body weight. After initiation of the treatment, patients were carried to the ambulance and immediately transferred to the hospital. They were continuously monitored by pulseoximetry, electrocardiography and oscillometric blood pressure measurements. Values for SpO 2 , heart rate and blood pressure were taken before the start of therapy, before the transport to hospital, immediately after the hospital arrival, and 30, 60 and 120 min after arrival. Additionally, dyspnea was graded according to a dyspnea scale before treatment and after hospital arrival (0-10; 0, no effort and 10, exhaustion).
The primary study end point was oxygen saturation at the time of hospital admission. After arrival in the hospital an experienced in-hospital physician decided how to continue the therapy according to the patients' state on admission. A blood sample was collected to measure the brain natriuretic peptide (BNP) known to be specifically elevated in ACPE and troponin T. The study was approved by the local ethics committee and written informed consent was obtained from all patients. The two groups were compared by Mann-Whitney U-test for unpaired samples. P < 0.05 was considered significant. Values are given as means ± SEM.
Results
Twenty-three patients were enrolled in the study. Thirteen patients were assigned to the standard treatment group and 10 to the NIPSV group. A higher furosemide dose was administered to the patients in the standard treatment group, whereas the sublingually administered nitroglycerin dose did not differ between the groups (Table 1) . Morphine sulfate was administered in bolus doses to six patients in the standard treatment group in a mean dosage of 7.3 ± 1.0 mg. The time treatment at the patients' home and the duration of the transport did not differ between the groups (Table 1 ). In the NIPSV group, the patients were ventilated with an endexpiratory pressure of 5 cm water according to the protocol and a pressure support of 12.5 ± 1.2 cm water. No problems in handling the ventilator and no adverse BNP, brain natriuretic peptide; NIPSV, noninvasive pressure support ventilation. *P < 0.05; # P = 0.06. 
Arrival in hospital
Beginning of transport incidents owing to NIPSV were noted. In seven patients, the NIPSV was discontinued in the hospital by the decision of the admitting physician owing to the considerably improved condition of the patient.
NIPSV had a clear beneficial effect on SpO 2 which rose immediately after initiation of ventilatory support resulting in significantly increased oxygen saturation before the start of the transport to the hospital (Fig. 1 ). This increase was significantly more pronounced than in the standard therapy group. The beneficial effect on oxygenation continued and SpO 2 increased further during the transport. At hospital arrival, SpO 2 was considerably higher in the NIPSV group compared with the standard treatment group (NIPSV, 97.3 ± 0.8%; standard treatment, 89.5 ± 2.7%; P = 0.002; Fig. 1 ). Standard therapy induced a smaller increase of SpO 2 after treatment initiation but no further improvement during transport to the hospital occurred. After 60 min of hospital admission and after ventilatory support had been finished in most patients, SpO 2 had slightly decreased in the NIPSV group and was further improved in the standard treatment group which resulted in nearly identical SpO 2 levels for both groups.
Heart rate, blood pressure and dyspnea rating did not differ between the groups throughout the observation time (Fig. 2) . The time in hospital or on intensive care unit did not differ between the groups (Table 1) . A clear trend towards higher troponin T levels was observed in the standard therapy group (Table 1 ; P = 0.062). BNP levels were elevated and did not differ between treatment groups. One patient in each group died in the hospital.
Discussion
The main result of this study is that prehospital NIPSV rapidly and substantially improves oxygen saturation in patients with ACPE. The recovery of oxygen saturation within minutes after initiation of NIPSV is closely consistent with the results of inpatient studies on NIPSV in ACPE on Intensive Care Units [1] . Moreover, prehospital NIPSV obviously further improves patients' condition due to its timely administration and results in measurable benefits for structural myocardial integrity. The study also shows that NIPSV is feasible for prehospital use. Both treatment groups did not differ in severity of heart failure as indicated by the initial BNP level.
Inpatient studies on NIPSV demonstrated a rapid lowering of respiratory rate and an early improvement of arterial pH, lactate concentration, blood pressure and heart rate [1] . A fast decrease in heart rate, dyspnea rating and systolic blood pressure was seen in both treatment groups in our study but significant treatment effects were not observed. This is in line with a previous inpatient study showing that the NIPSV needs to be continued for 1 h before its additional beneficial effects are reflected in secondary respiratory or hemodynamic parameters [1] . Thus, it is not astonishing that NIPSV did not cause any difference in these parameters because it was finished with the end of the prehospital phase after around 37 min in seven out of 10 patients. The parameters chosen to support patients' ventilation resembled much ventilatory parameters in a study which compared prehospital bilevel pressure controlled ventilation with high-dose intravenous isosorbide-dinitrate therapy for the treatment of lung edema (IPAP 9.3 ± 2.3 and EPAP 4.2 ± 3.1 mmHg; mean ± standard deviation) [9] . In this study, the BiPAP ventilation resulted in worse oxygen saturation compared with the treatment with nitroglycerin combined with oxygen via face mask (10 l/min). Our study differed from this study in two important aspects. First, both treatment conditions in our study allowed a standard drug regimen according to the clinical judgment of the emergency doctor and the ventilatory support was an add-on treatment solely replacing the oxygen supply via Venturi face mask. Second, our ventilation regimen offered coordinated ventilatory support of spontaneous breathing. This ventilatory mode might be less stressful than untriggered bilevel pressure ventilation in a situation of profound dyspnea with strong increase in ventilatory drive. On this background, patients experience a triggered pressure support as a rapid lowering of breathing work whereas bilevel pressure ventilation might induce fighting against the ventilator and even increase breathing effort and oxygen consumption. In this respect, it could be important for the prehospital setting, that the patient is instantly able to recognize the benefits of the ventilatory support in face of the life-threatening dyspnea. On the other hand, the technical complexity of NIPSV for the emergency team may cause prolongation of the prehospital treatment phase. In our study technical problems did not occur and NIPSV did not prolong the preclinical treatment time neither at home nor during the transport phase.
Although oxygen saturation was significantly improved by NIPSV, mortality, time in hospital, and need for intensive care therapy did not differ between the treatment conditions. These end points obviously need higher numbers of patients to be included in the study. Another finding of this study is, however, the trend towards higher troponin T levels in the standard treatment group. Troponin is an indicator of myocardial damage and the difference in troponin T levels indicates that NIPSV could have the potential to save myocardial tissue. This effect was either due to a better oxygenation and/or to the fact that positive airway pressure has favorable effects on the left ventricular transmural pressure in heart failure [10] .
In retrospect, this study was not powered for end points such as troponin T levels, need for intensive care therapy and mortality. It is possible that an early improvement of SpO 2 and possible favorable hemodynamic effects are able to improve patients' clinical outcome. Only a better outcome would justify the effort of NIPSV in a prehospital setting. A larger number of patients are therefore necessary to prove whether prehospital NIPSV has a long-term beneficial effect for the patients.
In conclusion, the study suggests that adjunctive prehospital NIPSV in acute heart failure with pulmonary edema is feasible and safe in a preclinical emergency setting and does not delay the transfer to hospital. It rapidly normalizes oxygen saturation and may offer cardioprotective effects. Thus, NIPSV seems beneficial for the prehospital treatment of cardiac pulmonary edema and deserves evaluation in larger multicenter studies.
